What is Processa Pharmaceuticals Inc's earnings per share (EPS)?

Processa Pharmaceuticals Inc (PCSA) reported diluted earnings per share of $-10.36 for fiscal year 2025. This represents a -167.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Processa Pharmaceuticals Inc Financials

PCSA

Source SEC Filings (10-K/10-Q) Updated Mar 18, 2026 Currency USD FYE March

This page shows Processa Pharmaceuticals Inc (PCSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Processa Pharmaceuticals Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, Processa Pharmaceuticals Inc generates $0.84 in operating cash flow (-$11.4M OCF vs -$13.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$14.0M

YoY-16.1%

Processa Pharmaceuticals Inc's EBITDA was -$14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 16.1% from the prior year.

Net Income

-$13.6M

YoY-14.5%

Processa Pharmaceuticals Inc reported -$13.6M in net income in fiscal year 2025. This represents a decrease of 14.5% from the prior year.

EPS (Diluted)

$-10.36

YoY-167.7%

Processa Pharmaceuticals Inc earned $-10.36 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 167.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.5M

YoY+364.8%

5Y CAGR-18.5%

10Y CAGR+119.9%

Processa Pharmaceuticals Inc held $5.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY-28.2%

Processa Pharmaceuticals Inc had 3M shares outstanding in fiscal year 2025. This represents a decrease of 28.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-243.2%

YoY+455.4pp

5Y CAGR-180.4pp

Processa Pharmaceuticals Inc's ROE was -243.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 455.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.6M

YoY-78.4%

5Y CAGR-13.1%

10Y CAGR+48.9%

Processa Pharmaceuticals Inc invested $1.6M in research and development in fiscal year 2025. This represents a decrease of 78.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

PCSA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$0	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.6M-78.4%	$7.3M+25.3%	$5.8M-49.5%	$11.5M+67.1%	$6.9M+116.8%	$3.2M
SG&A Expenses	$6.2M+29.2%	$4.8M-15.5%	$5.7M-35.4%	$8.8M+86.9%	$4.7M+43.6%	$3.3M
Operating Income	-$14.0M-16.1%	-$12.1M-5.2%	-$11.5M+58.4%	-$27.5M-126.9%	-$12.1M+19.8%	-$15.1M
Interest Expense	N/A	N/A	N/A	N/A	$362-99.9%	$281K
Income Tax	N/A	N/A	N/A	N/A	-$531K+47.0%	-$1.0M
Net Income	-$13.6M-14.5%	-$11.9M-6.6%	-$11.1M+59.4%	-$27.4M-140.0%	-$11.4M+20.7%	-$14.4M
EPS (Diluted)	$-10.36-167.7%	$-3.87+54.4%	$-8.48+75.1%	$-34.05	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.7M-32.1%	$2.4M+54.1%	$1.6M	N/A	$2.3M+32.2%	$1.7M+12.4%	$1.5M	N/A
SG&A Expenses	$1.8M+21.5%	$1.5M+19.5%	$1.3M	N/A	$1.1M-15.9%	$1.4M+6.4%	$1.3M	N/A
Operating Income	-$3.5M+11.7%	-$4.0M-38.8%	-$2.8M	N/A	-$3.4M-11.1%	-$3.1M-9.7%	-$2.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.4M+12.6%	-$3.9M-38.8%	-$2.8M	N/A	-$3.4M-12.4%	-$3.0M-10.4%	-$2.7M	N/A
EPS (Diluted)	$-0.07+72.0%	$-0.25	$-0.30	N/A	$-1.03-2.0%	$-1.01+9.0%	$-1.11	N/A

PCSA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.8M+142.0%	$3.2M-44.2%	$5.8M-32.9%	$8.6M-67.4%	$26.5M+5.0%	$25.2M
Current Assets	$5.7M+201.8%	$1.9M-66.6%	$5.6M-32.8%	$8.4M-54.2%	$18.3M+13.1%	$16.2M
Cash & Equivalents	$5.5M+364.8%	$1.2M-74.7%	$4.7M-27.6%	$6.5M-60.6%	$16.5M+7.0%	$15.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M+45.9%	$1.5M+92.2%	$797K-30.6%	$1.1M+17.4%	$978K-57.0%	$2.3M
Current Liabilities	$2.2M+45.9%	$1.5M+109.8%	$731K-26.8%	$999K+2.8%	$971K-20.5%	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.6M+228.8%	$1.7M-66.0%	$5.0M-33.2%	$7.5M-70.7%	$25.5M+11.1%	$22.9M
Retained Earnings	-$100.8M-15.6%	-$87.2M-15.7%	-$75.4M-17.3%	-$64.2M-74.5%	-$36.8M-45.0%	-$25.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.6M-7.3%	$8.2M+70.1%	$4.8M+48.9%	$3.2M-34.7%	$4.9M-35.0%	$7.6M-23.6%	$9.9M+71.9%	$5.8M
Current Assets	$6.6M-7.9%	$7.2M+90.4%	$3.8M+100.0%	$1.9M-61.2%	$4.8M-35.3%	$7.5M-23.7%	$9.8M+74.0%	$5.6M
Cash & Equivalents	$6.3M-9.1%	$6.9M+139.4%	$2.9M+143.2%	$1.2M-58.8%	$2.9M-48.1%	$5.6M-37.5%	$8.9M+89.5%	$4.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M-15.6%	$2.1M+61.7%	$1.3M-16.3%	$1.5M+25.5%	$1.2M-22.6%	$1.6M+48.6%	$1.1M+33.1%	$797K
Current Liabilities	$1.8M-15.6%	$2.1M+61.7%	$1.3M-16.3%	$1.5M+25.7%	$1.2M-21.4%	$1.6M+53.5%	$1.0M+38.3%	$731K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.8M-4.5%	$6.1M+73.2%	$3.5M+107.9%	$1.7M-54.4%	$3.7M-38.2%	$6.0M-32.2%	$8.9M+78.1%	$5.0M
Retained Earnings	-$97.4M-3.7%	-$94.0M-4.4%	-$90.1M-3.2%	-$87.2M-3.2%	-$84.5M-4.2%	-$81.1M-3.9%	-$78.1M-3.6%	-$75.4M

PCSA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$11.4M-1.2%	-$11.2M-39.5%	-$8.1M+16.1%	-$9.6M-10.2%	-$8.7M-177.3%	-$3.1M
Capital Expenditures	N/A	$3K+16.9%	$3K	N/A	N/A	N/A
Free Cash Flow	N/A	-$11.2M-39.5%	-$8.1M	N/A	N/A	N/A
Investing Cash Flow	-$850K-26102.2%	-$3K-16.9%	-$3K	N/A	N/A	N/A
Financing Cash Flow	$16.6M+114.4%	$7.7M+23.4%	$6.3M+1712.1%	-$389K-104.0%	$9.8M-45.2%	$17.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$300K	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.5M-53.5%	-$2.3M+16.8%	-$2.7M-21.4%	-$2.2M+37.6%	-$3.6M-7.7%	-$3.3M-63.3%	-$2.0M+3.5%	-$2.1M
Capital Expenditures	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	-$2.2M	N/A	N/A	N/A	-$2.1M
Investing Cash Flow	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0
Financing Cash Flow	$2.9M-54.7%	$6.3M+42.3%	$4.4M+710.0%	$548K-40.9%	$926K+27229.3%	-$3K-100.1%	$6.3M+20562.8%	-$31K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PCSA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-243.2%+455.4pp	-698.6%-475.7pp	-222.9%+144.2pp	-367.1%-322.3pp	-44.8%+18.0pp	-62.8%
Return on Assets	-173.6%+193.4pp	-367.0%-174.8pp	-192.2%+126.0pp	-318.2%-275.0pp	-43.2%+14.0pp	-57.2%
Current Ratio	2.54+1.3	1.23-6.5	7.71-0.7	8.40-10.5	18.87+5.6	13.27
Debt-to-Equity	0.40-0.5	0.90+0.7	0.160.0	0.15+0.1	0.04-0.1	0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-58.9%+5.5pp	-64.4%+16.0pp	-80.4%	N/A	-91.0%-41.0pp	-50.0%-19.3pp	-30.7%	N/A
Return on Assets	-45.3%+2.8pp	-48.1%+10.9pp	-58.9%	N/A	-68.5%-28.9pp	-39.6%-12.2pp	-27.4%	N/A
Current Ratio	3.76+0.3	3.45+0.5	2.93+1.7	1.23-2.7	3.97-0.9	4.82-4.9	9.70+2.0	7.71
Debt-to-Equity	0.30-0.0	0.34-0.0	0.36-0.5	0.90+0.6	0.33+0.1	0.26+0.1	0.12-0.0	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Bolt Biotherapeutics, Inc. BOLT

$8.7M

Cyclacel Phar Pr CYCCP

$9.6M

In8Bio, Inc. INAB

$13.8M

Dogwood Therapeutics DWTX

$71.1M

Transcode Therapeutics Inc RNAZ

$8.0M

Frequently Asked Questions

Is Processa Pharmaceuticals Inc profitable?

No, Processa Pharmaceuticals Inc (PCSA) reported a net income of -$13.6M in fiscal year 2025.

What is Processa Pharmaceuticals Inc's EBITDA?

Processa Pharmaceuticals Inc (PCSA) had EBITDA of -$14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Processa Pharmaceuticals Inc's return on equity (ROE)?

Processa Pharmaceuticals Inc (PCSA) has a return on equity of -243.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Processa Pharmaceuticals Inc's operating cash flow?

Processa Pharmaceuticals Inc (PCSA) generated -$11.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Processa Pharmaceuticals Inc's total assets?

Processa Pharmaceuticals Inc (PCSA) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Processa Pharmaceuticals Inc spend on research and development?

Processa Pharmaceuticals Inc (PCSA) invested $1.6M in research and development during fiscal year 2025.

How many shares does Processa Pharmaceuticals Inc have outstanding?

Processa Pharmaceuticals Inc (PCSA) had 3M shares outstanding as of fiscal year 2025.

What is Processa Pharmaceuticals Inc's current ratio?

Processa Pharmaceuticals Inc (PCSA) had a current ratio of 2.54 as of fiscal year 2025, which is generally considered healthy.

What is Processa Pharmaceuticals Inc's debt-to-equity ratio?

Processa Pharmaceuticals Inc (PCSA) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Processa Pharmaceuticals Inc's return on assets (ROA)?

Processa Pharmaceuticals Inc (PCSA) had a return on assets of -173.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Processa Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Processa Pharmaceuticals Inc (PCSA) had $5.5M in cash against an annual operating cash burn of $11.4M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Processa Pharmaceuticals Inc's Piotroski F-Score?

Processa Pharmaceuticals Inc (PCSA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Processa Pharmaceuticals Inc's earnings high quality?

Processa Pharmaceuticals Inc (PCSA) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.